Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
EUCTR |
Last refreshed on:
|
12 June 2012 |
Main ID: |
EUCTR2009-017961-52-SK |
Date of registration:
|
13/04/2010 |
Prospective Registration:
|
Yes |
Primary sponsor: |
|
Public title:
|
A 12-week, multi-center,randomized, double-blind, placebo-controlled efficacy and safety study examining seizure frequency of BGG492 capsules administration orally three times daily (TID) as adjunctive treatment in patients with partial onset seizures.
|
Scientific title:
|
A 12-week, multi-center,randomized, double-blind, placebo-controlled efficacy and safety study examining seizure frequency of BGG492 capsules administration orally three times daily (TID) as adjunctive treatment in patients with partial onset seizures. |
Date of first enrolment:
|
24/09/2010 |
Target sample size:
|
81 |
Recruitment status: |
Not Recruiting |
URL:
|
https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2009-017961-52 |
Study type:
|
Interventional clinical trial of medicinal product |
Study design:
|
Controlled: yes
Randomised: yes
Open: no
Single blind: no
Double blind: yes
Parallel group: no
Cross over: no
Other: no
If controlled, specify comparator, Other Medicinial Product: no
Placebo: yes
Other: no
|
Phase:
|
|
|
Countries of recruitment
|
Germany
|
Hungary
|
Italy
|
Slovakia
| | | | |
Contacts
|
Name:
|
|
Address:
|
|
Telephone:
|
|
Email:
|
|
Affiliation:
|
|
|
Name:
|
|
Address:
|
|
Telephone:
|
|
Email:
|
|
Affiliation:
|
|
| |
Key inclusion & exclusion criteria
|
Inclusion criteria: Key inclusion criteria: - male or female - weight sup or equal to 50kg - have a diagnosis of epilepsy ( For Cohort 1 abnormal EEG more than 2 years prior to screening) with partial seizures with or without secondarily generalizations seizures. For Cohort 2 the abnormal EEG at any time prior to screening. - have uncontrolled partial seizures - have at least 4 partial seizures - have no 28-day seizure-free period during the 8 weeks preceding randomization - Cohort 1 pstients must be receiving stable treatment with 1 or a maximum of 2 AEDs, whereas Cohort 2 patients must be receiving stable treatment with 1, 2 or 3 AEDs. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range
Exclusion criteria: Key exclusion criteria:Any of the following seizure conditions: - Presence of only non-motor simple partial seizures - Pschogenic seizures within 52 weeks prior to screening - Absences and/or myoclonic seizures e.g. in the context of primarily generalized epilepsy - Previous history of Lennox-Gastaut syndrome - Status epilepticus or seizure clusters where individual seizures cannot be counted according to the judgement of the investigator occuring within 52 weeks prior to randomization
For other criteria, please refer to the Protocol.
Age minimum:
Age maximum:
Gender:
Female: yes Male: yes
|
Health Condition(s) or Problem(s) studied
|
refractory partial-onset seizures MedDRA version: 12.1
Level: LLT
Classification code 10065336
Term: Partial epilepsy
|
Intervention(s)
|
Product Name: Not Available Product Code: BGG492 Pharmaceutical Form: Capsule, hard INN or Proposed INN: BGG492 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5-50 Pharmaceutical form of the placebo: Capsule, hard Route of administration of the placebo: Oral use
|
Primary Outcome(s)
|
Primary end point(s): Primary efficacy assessment: seizure counts (partial seizures only)during the 28-day baseline period and the week 7-10 maintenance period in comparison to placebo.
|
Secondary Objective: Key Secondary objective: to evaluate the efficacy of BGG492 (100 mg, 150 mg) administered orally TID compared to placebo assessed as change in seizure frequency from the 4-week baseline period (Weeks -4 to-1) to the 4-week double-blind maintenance period (Weeks 7 to 10).
|
Main Objective: Detect a dose-response of BGG492 as measured by change in seizure frequency from the 4-week baseline period (week -4 to .1) to the 4-week double-blind maintenance period (weeks 7 to 10).
|
Secondary ID(s)
|
2009-017961-52-DE
|
CBGG492A2207
|
Source(s) of Monetary Support
|
Results
|
Results available:
|
|
Date Posted:
|
|
Date Completed:
|
|
URL:
|
|
|
|